SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lundgren Jakob)
 

Sökning: WFRF:(Lundgren Jakob) > (2010-2014) > Pathophysiology and...

Pathophysiology and Potential Treatments of Pulmonary Hypertension due to Systolic Left Heart Failure.

Lundgren, Jakob (författare)
Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
Rådegran, Göran (författare)
Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
 (creator_code:org_t)
2014-05-16
2014
Engelska.
Ingår i: Acta Physiologica. - : Wiley. - 1748-1716 .- 1748-1708. ; 211:2, s. 314-333
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • Pulmonary hypertension (PH) due to left heart failure is becoming increasingly prevalent, and is associated with poor outcome. The precise pathophysiological mechanisms behind PH due to left heart failure are, however, still unclear. In its early course, PH is caused by elevated left ventricular filling pressures, without pulmonary vessel abnormalities. Conventional treatment for heart failure may partly reverse such passive PH by optimizing left ventricular function. However, if elevated pulmonary pressures persists, endothelial damage, excessive vasoconstriction and structural changes in the pulmonary vasculature may occur. There is, at present, no recommended medical treatment for this active component of PH due to left heart failure. However, as the vascular changes in PH due to left heart failure may be similar to those in pulmonary arterial hypertension (PAH), a selected group of these patients may benefit from PAH treatment targeting the endothelin, nitric oxide or prostacyclin pathways. Such potent pulmonary vasodilators could, however, be detrimental in patients with left heart failure without pulmonary vascular pathology, as selective pulmonary vasodilatation may lead to further congestion in the pulmonary circuit, resulting in pulmonary oedema. The use of PAH therapies is therefore, currently not recommended, and would require the selection of suitable patients based on the underlying causes of the disease, and careful monitoring of their progress. The present review focuses on: i. the pathophysiology behind PH resulting from systolic left heart failure and: ii. the current evidence for medical treatment of this condition, especially the role of PAH-targeted therapies in systolic left heart failure. This article is protected by copyright. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Fysiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Physiology (hsv//eng)

Publikations- och innehållstyp

for (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Lundgren, Jakob
Rådegran, Göran
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Medicinska och f ...
och Fysiologi
Artiklar i publikationen
Acta Physiologic ...
Av lärosätet
Lunds universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy